Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension

An 8-week, randomized, double-blind, factorial, phase II, multicenter study

Chang Gyu Park, Ho Joong Youn, Shung Chull Chae, Joo Young Yang, Moo Hyun Kim, Taek Jong Hong, Cheol Ho Kim, Jae Joong Kim, Bum Kee Hong, Jin Won Jeong, Si Hoon Park, Jun Kwan, Young Jin Choi, Seung Yun Cho

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5mg or 10 mg, losartan 50mg or 100 mg, amlodipine camsylate/losartan 5mg/50 mg, 5mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5mg/100mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension.

Original languageEnglish
Pages (from-to)35-47
Number of pages13
JournalAmerican Journal of Cardiovascular Drugs
Volume12
Issue number1
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Amlodipine
Losartan
Multicenter Studies
Blood Pressure
Hospital Outpatient Clinics
Therapeutics
Safety
Essential Hypertension
Vital Signs
Physical Examination
Electrocardiography
Placebos
Outcome Assessment (Health Care)
Hypertension

Keywords

  • amlodipine
  • hypertension
  • losartan.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension : An 8-week, randomized, double-blind, factorial, phase II, multicenter study. / Park, Chang Gyu; Youn, Ho Joong; Chae, Shung Chull; Yang, Joo Young; Kim, Moo Hyun; Hong, Taek Jong; Kim, Cheol Ho; Kim, Jae Joong; Hong, Bum Kee; Jeong, Jin Won; Park, Si Hoon; Kwan, Jun; Choi, Young Jin; Cho, Seung Yun.

In: American Journal of Cardiovascular Drugs, Vol. 12, No. 1, 01.02.2012, p. 35-47.

Research output: Contribution to journalArticle

Park, Chang Gyu ; Youn, Ho Joong ; Chae, Shung Chull ; Yang, Joo Young ; Kim, Moo Hyun ; Hong, Taek Jong ; Kim, Cheol Ho ; Kim, Jae Joong ; Hong, Bum Kee ; Jeong, Jin Won ; Park, Si Hoon ; Kwan, Jun ; Choi, Young Jin ; Cho, Seung Yun. / Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension : An 8-week, randomized, double-blind, factorial, phase II, multicenter study. In: American Journal of Cardiovascular Drugs. 2012 ; Vol. 12, No. 1. pp. 35-47.
@article{369399b0028a4f1aa7ae7c4230ee987a,
title = "Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: An 8-week, randomized, double-blind, factorial, phase II, multicenter study",
abstract = "Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5mg or 10 mg, losartan 50mg or 100 mg, amlodipine camsylate/losartan 5mg/50 mg, 5mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9{\%}, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5mg/100mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension.",
keywords = "amlodipine, hypertension, losartan.",
author = "Park, {Chang Gyu} and Youn, {Ho Joong} and Chae, {Shung Chull} and Yang, {Joo Young} and Kim, {Moo Hyun} and Hong, {Taek Jong} and Kim, {Cheol Ho} and Kim, {Jae Joong} and Hong, {Bum Kee} and Jeong, {Jin Won} and Park, {Si Hoon} and Jun Kwan and Choi, {Young Jin} and Cho, {Seung Yun}",
year = "2012",
month = "2",
day = "1",
doi = "10.2165/11597170-000000000-00000",
language = "English",
volume = "12",
pages = "35--47",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension

T2 - An 8-week, randomized, double-blind, factorial, phase II, multicenter study

AU - Park, Chang Gyu

AU - Youn, Ho Joong

AU - Chae, Shung Chull

AU - Yang, Joo Young

AU - Kim, Moo Hyun

AU - Hong, Taek Jong

AU - Kim, Cheol Ho

AU - Kim, Jae Joong

AU - Hong, Bum Kee

AU - Jeong, Jin Won

AU - Park, Si Hoon

AU - Kwan, Jun

AU - Choi, Young Jin

AU - Cho, Seung Yun

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5mg or 10 mg, losartan 50mg or 100 mg, amlodipine camsylate/losartan 5mg/50 mg, 5mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5mg/100mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension.

AB - Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5mg or 10 mg, losartan 50mg or 100 mg, amlodipine camsylate/losartan 5mg/50 mg, 5mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5mg/100mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension.

KW - amlodipine

KW - hypertension

KW - losartan.

UR - http://www.scopus.com/inward/record.url?scp=84863023379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863023379&partnerID=8YFLogxK

U2 - 10.2165/11597170-000000000-00000

DO - 10.2165/11597170-000000000-00000

M3 - Article

VL - 12

SP - 35

EP - 47

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 1

ER -